RSV MAT-004 - A Phase II observer-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women and infants born to vaccinated mothers

  • Buttery, Jim (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date15/11/1914/11/24


  • phase 2 study
  • clinical trial
  • child health
  • influenza